###  [:house:返回首頁](https://github.com/ourhimalayas/txt)
---

## 最新比利時國家監測數據表明：低劑量羥氯喹顯著降低住院患者死亡率
`2020-09-01 19:24 Isaiah4031` [轉載自GNews](https://gnews.org/zh-hant/328637/)

![](https://s3.amazonaws.com/gnews-media-offload/wp-content/uploads/2020/09/01175558/HCQ_Belgium-photo169.png)
新聞簡述：2020年8月24日發表於國際醫學雜誌（International Journal of Antimicrobial Agents）的一篇文章，對比利時國家醫院監測數據中的住院患者的死亡率進行了回顧性分析。比利時8,075住院患者病例的大樣本顯示：服用低劑量羥氯喹（5天2400mg的單藥治療）的患者對比僅僅給予支持性護理的患者，死亡率下降超過30%。

[下載英文原文](https://www.sciencedirect.com/science/article/pii/S0924857920303423)

**Low-dose Hydroxychloroquine Therapy and Mortality in Hospitalized Patients with COVID-19: A Nationwide Observational Study of 8075 Participants**

**低劑量羥氯喹治療與COVID-19住院患者的死亡率：一個8075名參與者的全國性觀察研究**

Lucy Catteau, PharmD, PhD a, f, I, #, Nicolas Dauby, MD, PhD, b, c, d, f, i, #, Marion Montourcy, MS, c, a, f, i, Emmanuel Bottieau, MD, PhD, e, f, i, Joris Hautekiet, MS, c, a, g, f, i, Els Goetghebeur, PhD, f, i, g, Sabrina van Ierssel, MD, PhD, f, i, h, Els Duysburgh, MD, MPH, PhD, a, f, i, Herman Van Oyen, MD, DrPH, a, f, h, i, Chloé Wyndham-Thomas, MD, PhD, a, f, I, Dominique Van Beckhoven, MD, MS, c, a, f, i, Belgian Collaborative Group on COVID-19 hospital surveillance

a Epidemiology and Public Health, Sciensano, Brussels

b Department of Infectious Diseases, CHU Saint-Pierre, Brussels

c Institute for Medical Immunology, Université Libre de Bruxelles (ULB)

d Environmental Health Research Centre, Public Health School, Université Libre de Bruxelles (ULB), Brussels, Belgium

e Department of Clinical Sciences, Institute for Tropical Medicine, Antwerp

f Cancer Center, Sciensano, Brussels

g Department of Applied Mathematics, Computer Science and Statistics, Ghent University, Ghent, Belgium

h Department of General Internal Medicine, Infectious Diseases and Tropical Medicine, University Hospital Antwerp (UZA), Edegem, Belgium

i Public Health and Primary Care, Gent University, Gent

Available online 24 August 2020.

文章於2020年8月24日線上發表

**Highlights**

- Hydroxychloroquine (HCQ) 2400 mg during 5 days was used in Belgium for COVID-19
- Impact of HCQ on mortality among 8075 patients with COVID-19 was assessed
- Lower mortality in HCQ-treated patients as compared to supportive care
- Lower mortality is irrespective of symptoms duration

**要點**

- 比利時使用羥氯喹(HCQ)2400毫克，為期5天，用於COVID-19。
- 評估HCQ對8075名COVID-19患者死亡率的影響。
- 與支持性護理相比，接受HCQ治療的患者死亡率較低。
- 較低的死亡率與症狀持續時間無關。

**Abstract 摘要**

**Background 背景**

Hydroxychloroquine (HCQ) has been largely used and investigated as therapy of COVID-19 across various settings, at total dose usually ranging from 2400 mg to 9600 mg. In Belgium, off-label use of low-dose HCQ (2400 mg in total over five days) was recommended for hospitalized patients with COVID-19.

羥氯喹(HCQ)已在各種場合被廣泛用於COVID-19的治療與調查，總劑量通常在2400毫克至9600毫克之間。在比利時，建議住院COVID-19患者使用非標示低劑量HCQ（5天內總劑量2400mg）。

**Methods 方法**

We conducted a retrospective analysis of in-hospital mortality in the Belgian national COVID-19 hospital surveillance data. Patients treated either with HCQ alone and supportive care (HCQ group) were compared to patients treated with supportive care only (no-HCQ group) using a competing risks proportional hazards regression with discharge alive as competing risk, adjusted for demographic and clinical features with robust standard errors.

我們對比利時全國COVID-19醫院監測數據中的住院死亡率進行了回顧性分析。單獨接受HCQ和支持性護理治療的患者（HCQ組）與僅接受支持性護理治療的患者（無HCQ組）進行了比較，採用競爭性風險比例危險回歸，以活著出院作為競爭性風險，對人口學和臨床特徵進行調整，具有穩健標準差。

**Results 結果**

Of 8075 patients with complete discharge data on 24th of May and diagnosed before the 1st of May, 4542 received HCQ in monotherapy and 3533 were in the no-HCQ group. Death was reported in 804/4542 (17.7%) and 957/3533 (27.1%), respectively. In the multivariable analysis, the mortality was lower in the HCQ group compared to the no-HCQ group (adjusted hazard ratio [HR] 0.684, 95% confidence interval [CI] 0.617–0.758). Compared to the no-HCQ group, mortality in the HCQ group was reduced both in patients diagnosed ≤ 5 days (n=3975) and &gt; 5 days (n=3487) after symptom onset (adjusted HR 0.701, 95% CI 0.617–0.796 and adjusted HR 0.647, 95% CI 0.525–0.797, respectively).

在5月24日有完整出院資料、5月1日前確診的8075例患者中，4542例接受HCQ單藥治療，3533例為無HCQ組。死亡人數分別為804/4542（17.7%）和957/3533（27.1%）。在多變量分析中，與無HCQ組相比，HCQ組的死亡率更低（調整後的危險比[HR]0.684，95%置信區間[CI]0.617-0.758）。與無HCQ組相比，在症狀發生後≤5天（n=3975）和&gt;5天（n=3487）診斷的患者中，HCQ組的死亡率均有所降低（調整後HR 0.701，95% CI 0.617-0.796，調整後HR 0.647，95% CI 0.525-0.797）。

**Conclusions 結論**

Compared to supportive care only, low-dose HCQ monotherapy was independently associated with lower mortality in hospitalized patients with COVID-19 diagnosed and treated early or later after symptom onset.

與僅支持性護理相比，低劑量HCQ單藥治療與症狀發生後早期或晚期診斷和治療的COVID-19住院患者死亡率降低獨立相關。

**Keywords 關鍵字**

Hydroxychloroquine; COVID-19SARS-CoV-2; mortality; observational study

羥氯喹； COVID-19； SARS-CoV-2；死亡率；觀察性研究

**1. Introduction 介紹**

There is currently no robust antiviral or immunomodulatory treatment of SARS-CoV-2 infection, the causative agent of COVID-19. Chloroquine (CQ), an anti-malarial drug, has shown to have *in vitro* anti-viral properties against both SARS-CoV and SARS-CoV-2 by different mechanisms [\[1\]](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#bib0001), [\[2\]](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#bib0002), [\[3\]](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#bib0003), [\[4\]](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#bib0004). It has also been hypothesized that CQ could have a positive impact on COVID-19 outcome through immunomodulatory properties [[5](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#bib0005),[6](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#bib0006)]. Hydroxychloroquine (HCQ), a derivative of CQ, has a long clinical track record as treatment of malaria and inflammatory diseases, such as systemic lupus erythematous (SLE) and rheumatoid arthritis (RA), with a favorable safety profile in acute and chronic use [\[7\]](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#bib0007). Both CQ and HCQ were selected by the World Health Organization (WHO) for potential repurposing for COVID-19. Early during the amplification phase of the epidemic in Belgium, and pending results of clinical trials, off-label administration of a “low-dose” regimen of HCQ sulphate in monotherapy (400mg twice on day 1, followed by 200mg twice a day from day 2 to 5, i.e. a total dose of 2400 mg) was recommended as an acceptable immediate treatment option for hospitalized COVID-19 patients [\[8\]](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#bib0008). This guidance, officially released on March, 13th, was based on the following considerations: (1) HCQ was the only drug with demonstrated *in vitro* effect against SARS-CoV-2 available in Belgium at that time; (2) HCQ exhibited a superior *in vitro* antiviral effect in comparison to CQ, likely explained by the higher intracellular drug accumulated concentrations [\[9\]](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#bib0009); (3) limited pharmacokinetic data suggested that the selected dosage should have sufficient antiviral activity [\[10\]](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#bib0010); (4) chronic administration of HCQ for rheumatological disorders has not been associated with major safety signals since decades of use; (5) restricting HCQ use to well-selected COVID-19 patients monitored at hospitals appeared as a reasonable risk/benefit compromise considering the well-known dose-dependent cardiotoxicity of the drug; (6) it was advised to Belgian hospitals to administer this off-label regimen whenever possible within clinical studies. Of note, azithromycin (AZM) and systemic use of corticosteroids were not recommended in the guidance [\[8\]](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#bib0008). Simultaneously, Sciensano, the Belgian Scientific Institute of Public Health, initiated a national surveillance of COVID-19 hospitalized patients, that included treatments and outcomes among its variables, enabling the clinical surveillance of drug use and outcome.

對於COVID-19的致病菌SARS-CoV-2感染，目前尚無強有力的抗病毒或免疫調節治療。氯喹（Chloroquine，CQ）是一種抗瘧疾藥物，通過不同機制對SARS-CoV和SARS-CoV-2均有體外抗病毒作用  [1], [2], [3], [4]. 也有人推測CQ可以通過免疫調節特性對COVID-19的結果產生積極影[5,6]。羥氯喹（HCQ）是CQ的衍生物，作為治療瘧疾和炎症性疾病（如系統性紅斑狼瘡（SLE）和類風濕關節炎（RA））有長期的臨床記錄，在急性和慢性使用中具有良好的安全性 [7]。世界衛生組織（WHO）選擇CQ和HCQ都有可能重新用於COVID-19。早在比利時疫情擴大階段，在臨床試驗結果出來之前，就推薦了硫酸HCQ單藥治療的 “低劑量 “方案（第1天兩次400mg，第2天至第5天每天兩次200mg，即總劑量2400mg）作為住院COVID-19患者可接受的即時治療方案 [8]。該指南於3月13日正式發佈，是基於以下考慮。(1)HCQ是當時比利時唯一有體外抗SARS-CoV-2效果證明的藥物；(2)與CQ相比，HCQ表現出更優越的體外抗病毒效果，可能是由更高的細胞內藥物累積濃度來解釋的[9]；(3)有限的藥代動力學數據表明，所選劑量應具有足夠的抗病毒活性[10]。(4)自使用數十年以來，慢性給藥HCQ治療風濕性疾病並沒有出現重大的安全信號；(5)考慮到該藥眾所周知的劑量依賴性心臟毒性，將HCQ的使用限制在醫院監測的精心挑選的COVID-19患者中似乎是一種合理的風險/收益折衷方案；(6)建議比利時醫院在臨床研究範圍內盡可能地使用這種非標籤方案。值得注意的是，指南中並不推薦阿奇霉素（AZM）和全身使用皮質激素[8]。同時，比利時公共衛生科學研究所Sciensano啓動了對COVID-19住院患者的全國性監測，該監測的變量中包括治療和結果，從而實現了對藥物使用和結果的臨床監測。

So far, the impact of HCQ on the outcome of SARS-CoV-2 infection in humans remains undetermined. An increasing number of single- and multi-center retrospective studies using various HCQ dosages are being published with conflicting results  [\[11\]](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#bib0011), [\[12\]](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#bib0012), [\[13\]](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#bib0013), [\[14\]](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#bib0014), [\[15\]](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#bib0015), [\[16\]](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#bib0016), [\[17\]](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#bib0017), [\[18\]](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#bib0018), [\[19\]](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#bib0019). Recently, the UK-based RECOVERY and WHO-led SOLIDARITY trials communicated that HCQ at the study dosage of 9200 to 9600 mg over 10 days provided no benefit in hospitalized patients with COVID-19 [\[20\]](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#bib0020).

迄今為止，HCQ對人類感染SARS-CoV-2的結果的影響仍未確定。越來越多的使用不同HCQ劑量的單中心和多中心回顧性研究正在發表，結果相互矛盾[11], [12], [13], [14], [15], [16], [17], [18], [19]。最近，英國的RECOVERY試驗和WHO領導的SOLIDARITY試驗通報，研究劑量為9200～9600mg，10天的HCQ對住院的COVID-19患者沒有益處 [20]。

In the present study, we retrospectively assessed the association between HCQ monotherapy and in-hospital mortality in a nationwide registry of 8075 COVID-19 patients. Next, the impact of HCQ treatment on mortality was investigated according to the time between symptom onset and COVID-19 diagnosis.

在本研究中，我們回顧性地評估了全國8075例COVID-19患者的登記表中HCQ單藥治療與院內死亡率的關係。其次，根據症狀發生與COVID-19診斷之間的時間，研究HCQ治療對死亡率的影響。

**2. Methods 方法**

**2.1. Data collection 數據收集**

Sciensano’s data collection of patients hospitalized with confirmed COVID-19 was initiated on the 14th of March, two weeks after the first symptomatic case was reported in Belgium, and systematic registering was strongly encouraged by health authorities. Two independent online secured questionnaires in LimeSurvey (GmbH, Hamburg, Germany) were made available: one with information after admission and the second after discharge. Information collected at admission included socio-demographic characteristics, clinical presentation, comorbidities, chronic treatment with renin-angiotensin-aldosterone system inhibitors as well as diagnostic workup. Data collected at discharge included COVID-19 treatment details (antiviral and immunomodulatory drugs including date of initiation and termination, mode of administration), clinical and laboratory markers of severity during hospital stay, admission to intensive care unit (ICU), and final outcome at hospital discharge (dead or discharged alive).

Sciensano對確診的COVID-19住院患者的數據收集是在3月14日開始的，即在比利時報告第一例症狀病例兩周後，衛生當局大力鼓勵進行系統登記。在LimeSurvey（GmbH，德國漢堡）中提供了兩份獨立的在線安全問卷：一份是入院後的信息，另一份是出院後的信息。入院時收集的信息包括社會人口學特徵、臨床表現、合併症、腎素-血管緊張素-醛固酮系統抑制劑的慢性治療以及診斷工作。出院時收集的數據包括COVID-19治療細節(抗病毒和免疫調節藥物，包括開始和終止日期、給藥方式)、住院期間嚴重程度的臨床和實驗室標誌物、進入重症監護室(ICU)，以及出院時的最終結果(死亡或活著出院)。

**2.2. Hydroxychloroquine treatment 羥氯喹治療**

On the 13th of March, a task force (ND, SVI and EB, affiliated to the national reference institutions for emerging infections), coordinated by Sciensano, published a guidance for the management of patients hospitalized with COVID-19. Based on the above described rationale, the “low-dose” HCQ regimen (2400 mg in total over five days) was recommended as a reasonable emergency therapeutic option for hospitalized patients and was centrally provided for free [\[8\]](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#bib0008). A set of warnings were provided on its use, including QT corrected (QTc) determination in all admitted patients and close cardiac monitoring in case baseline QTC exceeded 450 msec and in all conditions that could favor arrhythmia (underlying cardiopathy, congenital or acquired QTc prolongation, electrolytic disturbances, or use of other drugs prolonging the QTc duration) [\[8\]](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#bib0008). Treatment initiation was advised as soon as diagnosis was made with information to the patient about the off-label use. Final treatment decision was however left at the discretion of the treating physician.

3月13日，在Sciensano的協調下，一個特別工作組（ND、SVI和EB，隸屬於國家新發感染參考機構）發佈了COVID-19住院患者管理指南。基於上述理由，推薦 “低劑量 “HCQ方案（5天共2400mg）作為住院患者合理的應急治療方案，並集中免費提供[8]。對其使用提出了一系列警告，包括對所有入院患者進行QT校正(QTc)測定，並在基線QTC超過450毫秒和所有可能有利於心律失常的條件下(潛在的心臟病、先天性或獲得性QTc延長、電解質紊亂或使用其他藥物延長QTc持續時間)進行密切的心臟監測[8]。一經診斷就建議開始治療，並向患者告知非標示使用情況。然而，最終的治療決定由主治醫生決定。

**2.3. Inclusion and exclusion criteria 納入和排除標準**

We analyzed all COVID-19 cases for whom both admission and discharge questionnaires were reported up to the 24th of May. The analysis was restricted to those confirmed before the 1st of May by RT-PCR and/or rapid antigen test on respiratory samples, with exclusion of those diagnosed by pulmonary CT Scan only. The SARS-CoV-2 rapid antigen test used in Belgium has a specificity of 99.5% compared to RT-PCR in respiratory samples [\[21\]](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#bib0021). Children below 16 years, pregnant and post-partum women as well as patients who were discharged (either alive or dead) within 24 hours after hospital admission or before diagnosis confirmation were excluded. In addition, we removed from this analysis all patients having started any COVID-19-related treatment before symptom onset, including for other clinical indications as well as those having a missing date of diagnosis. To compare patients treated with HCQ alone with those receiving only supportive care, patients treated with another COVID-19-related treatment (macrolides, tocilizumab, lopinavir/ritonavir, remdesivir, atazanavir or anakinra), whether prescribed with or without HCQ, were also excluded.

我們分析了截至5月24日，入院和出院問卷均有報告的所有COVID-19病例。分析僅限於5月1日前經呼吸道樣本RT-PCR和/或快速抗原檢測確認的病例，排除了僅經肺部CT掃描診斷的病例。比利時使用的SARS-CoV-2快速抗原檢測與呼吸道樣本的RT-PCR相比，特異性為99.5% [21]。我們排除了16歲以下兒童、孕婦和產後婦女以及入院後24小時內或確診前出院的患者（無論生或死）。此外，我們從本分析中剔除了所有在症狀發生前已開始任何COVID-19相關治療的患者，包括其他臨床適應症以及診斷日期缺失的患者。為了比較單獨接受HCQ治療的患者和僅接受支持性護理的患者，也排除了接受另一種COVID-19相關治療（大環內酯類、托西珠單抗、洛匹那韋/利托那韋、雷米替西韋、阿扎那韋或阿納金拉）的患者，無論是否有HCQ處方。

**2.4. Statistical analyses 統計學分析**

Participants meeting the inclusion criteria were divided into two groups: (1) COVID-19 patients treated with HCQ monotherapy in addition to supportive care (HCQ group) and (2) those receiving supportive care alone (no-HCQ group). Demographic characteristics, pre-existing conditions, laboratory parameters, clinical features and outcome were described first by discharge status (survivors versus non-survivors) and secondly by treatment group (HCQ versus no-HCQ). Chi-square tests for categorical variables and Wilcoxon tests for continuous variables were used to assess differences between groups. We considered a p value &lt; 0.05 to be statistically significant.

符合納入標準的參與者被分為兩組。(1) COVID-19患者除支持性護理外，還接受HCQ單藥治療(HCQ組)；(2) 單獨接受支持性護理的患者(無HCQ組)。首先按出院狀態（存活者與非存活者），其次按治療組（HCQ與no-HCQ）描述人口學特徵、已有條件、實驗室參數、臨床特徵和結果。分類變量的Chi-square檢驗和連續變量的Wilcoxon檢驗用於評估組間差異。我們認為p值&lt;0.05為有統計學意義。

Missing data among important prognostic baseline covariates were assumed to be missing at random, i.e. independent of the underlying missing values given the observed data. This was handled by tenfold multiple imputation performed in R software through the MICE package version 3.8.0 [\[22\]](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#bib0022). A competing risks proportional hazards regression with robust standard errors allowing for clustering within hospitals (R package SURVIVAL version 3.1-12) was then used to analyse in-hospital death competing with alive discharge from hospital. Hazards of this in-hospital death thus dropped to zero post discharge alive. Cause-specific hazards of treatment effect were adjusted for baseline covariates age, sex, comorbidities (cardiovascular disease, arterial hypertension, diabetes, chronic renal, liver and lung diseases, neurological and cognitive disorders, immunosuppressive conditions, malignancies, obesity and smoking status), clinical features (pneumonia diagnosis, acute respiratory distress syndrome, admission to intensive care unit within the 24h following admission, and the time from symptom onset to diagnosis, baseline laboratory parameters of disease severity consisting of lactate dehydrogenase (LDH) ≥ 350 IU/L, C reactive protein (CRP) ≥ 150 mg/L and partial pressure of oxygen (paO2) &lt; 60mmHg. As HCQ prescription decreased over time, calendar time of diagnosis was also included in the model.

假設重要的預後基線協變量中的缺失數據是隨機缺失的，即獨立於給定觀察數據的基本缺失值。這是由R軟件中通過MICE軟件包3.8.0版[22]進行的十倍多重歸因處理。然後使用具有穩健標準誤差的競合風險比例危害回歸，允許在醫院內進行聚類（R包survival 3.1-12版）來分析院內死亡與活著出院的競合。因此，這種院內死亡的危害性在出院後活體下降為零。治療效果的特異性危害調整了基線協變量年齡、性別、合併症（心血管疾病、動脈高血壓、糖尿病、慢性腎臟、肝臟和肺部疾病、神經和認知障礙、免疫抑制性疾病、惡性腫瘤、肥胖和吸煙狀態）、臨床特徵（肺炎診斷。急性呼吸窘迫綜合徵，入院後24h內進入重症監護室，以及從症狀發生到診斷的時間，疾病嚴重程度的基線實驗室參數包括乳酸脫氫酶（LDH）≥350IU/L，C反應蛋白（CRP）≥150mg/L，氧分壓（paO2）&lt;60mmHg。由於HCQ處方隨時間的推移而減少，模型中還包括診斷的日曆時間。

The propensity of HCQ treatment was estimated from those same baseline covariates (R package IPW version 1.0-11 [\[23\]](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#bib0023)). An inverse propensity weighted standardized cumulative incidence of in-hospital death for each treatment was derived using R package RISCA version 0.8.2 [\[24\]](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#bib0024). The competing risks analysis was repeated for patients treated within or beyond 5 days of onset of symptoms. Sensitivity analyses were performed (Supplemental Material): they considered additional adjustments in the model, missing data impact and possible immortal time bias associated with delayed treatment receipt. Analyses were performed in SAS Enterprise Guide 7.1 and in R 3.6.3.

根據這些相同的基線協變量估計HCQ治療的傾向性（R包IPW 1.0-11版 [23]）。使用R包RISCA 0.8.2版 [24]，得出每種治療的反傾向加權標準化累積住院死亡發生率。對症狀發生後5天內或5天以上接受治療的患者重復進行競爭性風險分析。進行了敏感性分析（補充材料）：它們考慮了模型中的額外調整、缺失數據影響和與延遲接受治療相關的可能不死時間偏差。分析是在SAS企業指南7.1和R 3.6.3中進行的。

**2.5. Ethical and privacy considerations 伦理和隐私方面的考虑**

The hospital data collection is being performed by Sciensano, the Belgian Scientific Institute of Public Health, legally entitled for surveillance of infectious diseases in Belgium (Royal Decree of 21/03/2018). This COVID-19 hospital surveillance was authorized by an independent administrative authority protecting privacy and personal data, and approved by the ethical committee of Ghent University Hospital (BC-07507).

醫院數據收集工作由比利時公共衛生科學研究所Sciensano進行，該研究所依法有權對比利時的傳染病進行監測（2018年3月21日皇家法令）。此次COVID-19醫院監測由一個獨立的保護隱私和個人數據的行政機構授權，並由根特大學醫院倫理委員會批准（BC-07507）。

**3. Results 結果**

As recorded on 24th of May, the Sciensano database contained a total of 15544 case records of COVID-19 patients ([Figure 1](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#fig0001)), originating from 109 Belgian hospitals. Among those, both admission and discharge report forms were received for 10920 patients (3311 [20%] discharge forms were missing for patients with admission data and 1313 [8%] admission forms were missing for patients with discharge data). After having excluding patients not meeting inclusion criteria ([Figure 1](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#fig0001)), 8910 cases were included for the descriptive analysis.

根據5月24日的記錄，Sciensano數據庫中共有15544例COVID-19患者的病例記錄（圖1），來自比利時109家醫院。其中，10920名患者同時收到了入院和出院報告表（3311名[20%]有入院數據的患者缺少出院表，1313名[8%]有出院數據的患者缺少入院表）。在排除不符合納入標準的患者後（圖1），8910例被納入描述性分析。

1. [Download : Download high-res image (374KB)](https://ars.els-cdn.com/content/image/1-s2.0-S0924857920303423-gr1_lrg.jpg)
2. [Download : Download full-size image](https://ars.els-cdn.com/content/image/1-s2.0-S0924857920303423-gr1.jpg)


Figure 1. Data flow of COVID-19 patients selection for the observational cohort study

圖一. 新冠患者回顧性研究患者數據流程圖
![](https://s3.amazonaws.com/gnews-media-offload/wp-content/uploads/2020/09/01191408/fig.1_Traditional-2-scaled.jpg)
About 60% of the hospitalized COVID-19 patients were aged above 65 years ([Table 1](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tbl0001)). In general, participants were severely ill with more than 80% having radiological pneumonia, large proportions presenting with laboratory parameters of severity, including pronounced hypoxemia, and 5% requiring immediate admission in intensive care unit (ICU). Median time from symptom onset to COVID-19 diagnosis was five days. Patients with incomplete discharge data (n=2332) were similar to the study population, in terms of age and sex distribution as well as frequency of pre-existing conditions, except from the proportion of active smokers (Supplemental Table 1). In univariate analysis, compared to survivors, non-survivors were older, more likely to be men and to suffer from pre-existing conditions ([Table 1](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tbl0001)). In addition, non-survivors presented more often with laboratory markers of severity such as high levels of lactate dehydrogenase (LDH&gt;350 IU/L) and C-reactive protein (CRP&gt;150 mg/L), and severe hypoxemia (paO2&lt;60 mmHg). Time from symptom onset to diagnosis was shorter in non-survivors (median 3 days, versus 6 days in survivors, *p* &lt; 0.0001). Length of hospital stay was similar in both groups.

約60%的住院COVID-19患者年齡在65歲以上（表1）。一般來說，參與者病情嚴重，80%以上有放射性肺炎，大比例的患者出現實驗室參數嚴重超標，包括明顯的低氧血症，5%的患者需要立即入住重症監護室（ICU）。從症狀發生到COVID-19診斷的中位時間為5天。出院數據不完整的患者（n=2332）與研究人群相似，除了從活躍的吸煙者的比例來看，在年齡和性別分布以及已有疾病的頻率方面都是如此（補充表1）。在單變量分析中，與存活者相比，非存活者年齡更大，更可能是男性，並患有原有疾病（表1）。此外，非幸存者更常出現實驗室標誌物嚴重超標，如高水平的乳酸脫氫酶（LDH&gt;350 IU/L）和C反應蛋白（CRP&gt;150 mg/L），以及嚴重的低氧血症（paO2&lt;60 mmHg）。非幸存者從症狀發生到診斷的時間較短（中位數為3天，而幸存者為6天，P &lt;0.0001）。兩組患者的住院時間相似。

Table 1. COVID-19 Patients (n=8910) characteristics by survival or non-survival status during hospitalization.

表1. COVID-19患者（n=8910）在住院期間按生存或非生存狀態劃分的特徵。COVID-19患者(n=8910)在住院期間按生存或非生存狀態劃分的特徵。


| <br> | *No./total No. (%)* |
| --- | --- |
| <br> | 總數 n=8910 | 幸存者 n=6981 | 非幸存者 n=1929 | *p* 值 |
| 人口特徵 |
| 年齡, 歲 | <br> | <br> | <br> | <br> |
|  16-30 | 149/8906 (1.7) | 149/6979 (2.1) | 0/1927 (0.0) | &lt;0.0001[\*](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb1fn3) |
|  31-44 | 607/8906 (6.8) | 596/6979 (8.5) | 11/1927 (0.6) | <br> |
|  45-64 | 2685/8906 (30.2) | 2503/6979 (35.9) | 182/1927 (9.4) | <br> |
|  65-79 | 2655/8906 (29.8) | 2017/6979 (28.9) | 638/1927 (33.1) | <br> |
|  &gt;80 | 2810/8906 (31.6) | 1714/6979 (24.6) | 1096/1927 (56.9) | <br> |
| 中位數(IQR) | 71 (57-82) | 66 (54-79) | 82 (73-87) | <br> |
| 男性 | 4807/8819 (54.5) | 3711/6919 (53.6) | 1096/1900 (57.7) | 0.0017[±](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb1fn4) |
| 既有病史 |
| 心血管疾病 | 3084/8910 (34.6) | 2093/6981 (30.0) | 991/1929 (51.4) | &lt;0.0001[±](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb1fn4) |
| 動脈高血壓 | 3622/8910 (40.7) | 2641/6981 (37.8) | 981/1929 (50.9) | &lt;0.0001[±](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb1fn4) |
| 糖尿病 | 1985/8910 (22.3) | 1442/6981 (20.7) | 543/1929 (28.1) | &lt;0.0001[±](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb1fn4) |
| 慢性腎病 | 1166/8910 (13.1) | 733/6981 (10.5) | 433/1929 (22.4) | &lt;0.0001[±](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb1fn4) |
| 慢性肝病 | 237/8910 (2.7) | 160/6981 (2.3) | 77/1929 (4.0) | &lt;0.0001[±](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb1fn4) |
| 慢性肺病 | 1353/8910 (15.2) | 976/6981 (14.0) | 377/1929 (19.5) | &lt;0.0001[±](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb1fn4) |
| 神經系統疾病 | 832/8910 (9.3) | 555/6981 (8.0) | 277/1929 (14.4) | &lt;0.0001[±](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb1fn4) |
| 認知障礙[1](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb1fn1) | 1001/8338 (12.0) | 627/6539 (9.6) | 374/1799 (20.8) | &lt;0.0001[±](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb1fn4) |
| 免疫抑制性疾病 惡性腫瘤 | 248/8910 (2.7) | 191/6981 (2.7) | 57/1929 (3.0) | 0.6049[±](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb1fn4) |
| 實體瘤 | 730/8910 (8.2) | 507/6981 (7.3) | 223/1929 (11.6) | &lt;0.0001[±](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb1fn4) |
| 血液系統腫瘤 | 174 /8910 (2.0) | 118/6981 (1.7) | 56/1929 (2.9) | 0.0007[±](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb1fn4) |
| 肥胖症[1](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb1fn1) | 545/5457 (10.0) | 450/4313 (10.4) | 95/1144 (8.3) | 0.0327[±](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb1fn4) |
| 目前吸煙者 | 407/4757 (8.6) | 312/3793 (8.2) | 95/964 (9.9) | 0.1064[±](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb1fn4) |
| 藥品 |
| 血管緊張素轉換酶抑制劑 | 1368/8907 (15.3) | 1030/6979 (14.8) | 338/1928 (17.5) | 0.0028[±](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb1fn4) |
| 血管緊張素受體阻斷劑 | 806/8907 (9.0) | 604/6979 (8.7) | 202/1928 (10.5) | 0.0135[±](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb1fn4) |
| *COVID-19*治療 |
| 只提供支持性護理 | 3533/8910 (39.6) | 2576/6981 (36.9) | 957/1929 (49.6) | &lt;0.0001[±](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb1fn4) |
| HCQ  | 4542/8910 (51.0) | 3738/6981 (53.5) | 804/1929 (41.7) | &lt;0.0001[±](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb1fn4) |
| HCQ + 大環內酯類 | 761/8910 (8.5) | 617/6981 (8.5) | 144/1929 (7.5) | 0.0561[±](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb1fn4) |
| 羅匹那韋/利托那韋 | 12/8910 (0.1) | 7/6981 (0.1) | 5/1929 (0.3) | 0.2358[±](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb1fn4) |
| HCQ + 羅匹那韋/利托那韋 | 18/8910 (0.2) | 10/6981 (0.1) | 8 /1929 (0.4) | 0.0504[±](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb1fn4) |
| HCQ +托珠單抗 | 17/8910 (0.2) | 12/6981 (0.2) | 5/1929 (0.3) | 0.4367[±](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb1fn4) |
| HCQ +托珠單抗+ 大環內酯類 | 7/8910 (0.1) | 5/6981 (0.1) | 2/1929 (0.1) | 0.6565[±](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb1fn4) |
| HCQ + 瑞德西韋 | 4/8910 (0.0) | 2/6981 (0.0) | 2/1929 (0.1) | 0.1685[±](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb1fn4) |
| 其它 | 16/8910 (0.2) | 14/6981 (0.2) | 2/1929 (0.1) | 0.3738[±](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb1fn4) |
| 實驗室參數 |
| 乳酸脫氫酶(IU/L) | <br> | <br> | <br> | <br> |
|   中位數(IQR) | 343 (258-477) [7385] | 329 (251-459) [5909] | 394 (288-548)[1476] | &lt;0.0001[\*](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb1fn3) |
|   &gt;350 | 3563/7385 (48.2) | 2663/5909 (45.1) | 900/1476 (61.0) | &lt;0.0001[±](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb1fn4) |
| C-反應蛋白(mg/L) | <br> | <br> | <br> | <br> |
|  中位數(IQR) | 62 (26-118) [8624] | 55.9 (21.8-108.2) [6802] | 91.2 (44.4-162) [1822] | &lt;0.0001[\*](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb1fn3) |
|   &gt;150 | 1487/8624 (17.2) | 973/6802 (14.3) | 514/1822 (28.2) | &lt;0.0001[±](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb1fn4) |
| paO2 (mmHg) | <br> | <br> | <br> | <br> |
|  中位數(IQR) | 66 (57-76) [6013] | 67 (70-77) [4713] | 61 (52-73) [1300] | &lt;0.0001[\*](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb1fn3) |
|   &lt;60 | 1834/6013 (30.5) | 1221/4713 (25.9) | 613/1300 (47.2) | &lt;0.0001[±](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb1fn4) |
| 臨床特徵 | <br> | <br> | <br> | <br> |
| 肺炎[2](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb1fn2) | 7184/8567 (83.9) | 5545/6710 (82.6) | 1639/1857 (88.2) | &lt;0.0001[±](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb1fn4) |
| 急性呼吸窘迫綜合症 | 1197/8423 (14.2) | 601/6710 (9.0) | 596/1713 (34.8) | &lt;0.0001[±](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb1fn4) |
| 有創通氣支持 | 736/8691 (8.5) | 367/6810 (5.4) | 369/1881 (19.6) | &lt;0.0001[±](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb1fn4) |
| 入院後24小時內進入重症監護室的情況 | 488/8900 (5.5) | 298/6974 (4.3) | 190/1926 (9.9) | &lt;0.0001[±](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb1fn4) |
| 從症狀發生到診斷的時間（天），中位數（IQR） [編號] | 5 (2-9) [8097] | 6 (2-9) [6393] | 3 (1-7) [1704] | &lt;0.0001[\*](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb1fn3) |
| 住院時間（天數）， 中位數（IQR）[編號] | 9 (5-15) [8894] | 9 (5-15) [6970] | 9 (5-16) [1924] | 0.9320[\*](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb1fn3) |


All the pre-existing conditions and COVID-19 features were reported as assessed by the clinician.

經臨床醫生評估，報告了所有已存在的疾病和COVID-19特徵。

HCQ：羥氯喹；IQR：四分位數範圍；paO2：氧分壓

1 缺失是由於數據收集開始的時間較晚。

2 影像學診斷(Rx和/或CT胸腔)

⁎ Wilcoxon檢驗

± Chi-Square檢驗

After further exclusion of patients who received alternative COVID-19 treatments with (n=818, including macrolides, n=761) or without HCQ (n=17), the comparative analysis was restricted to 8075 subjects: 4542 in the HCQ group and 3533 in the no-HCQ group ([Fig 1](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#fig0001)). Of the HCQ-treated patients, 78.2% initiated the treatment within 24h after diagnosis.

在進一步排除接受其他COVID-19治療的患者後，對接受HCQ（n=818，包括大環內酯類，n=761）或不接受HCQ（n=17）的患者進行比較分析，比較分析僅限於8075名受試者。HCQ組4542人，無HCQ組3533人（圖1）。在HCQ治療的患者中，78.2%的患者在診斷後24h內開始治療。

As shown in [Table 2](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tbl0002), COVID-19 patients in the HCQ group were younger and male sex was predominant. Several comorbidities were significantly less frequent in the HCQ group, including cardiovascular diseases, arterial hypertension, chronic renal disease, neurological and cognitive disorders, solid cancer, obesity as well as the proportion of active smokers. On the other hand, at admission, patients in the HCQ group appeared to be sicker as reflected by the higher frequency of radiological pneumonia, acute respiratory distress syndrome, ICU transfer within the 24h after admission and invasive ventilation support as well as the higher frequency of elevated LDH and CRP levels. The case fatality rate of the study population was 21.8% (1761 deaths/8075 patients) but was lower in the HCQ group (804/4542, 17.7%) than in the no-HCQ group (957/3533, 27.1%, p&lt;0.001). Incidental use of steroids was very low in both groups, although slightly higher in the HCQ group (8.1% vs 5.9% respectively). On a side note, mortality in the 761 participants who received HCQ and AZM was 18.9%.

如表2所示，HCQ組的COVID-19患者年齡較小，男性性別居多。HCQ組的幾種合併症明顯較少，包括心血管疾病、動脈高血壓、慢性腎臟疾病、神經系統和認知障礙、實體癌、肥胖以及活躍的吸煙者比例。另一方面，在入院時，HCQ組患者的病情似乎更嚴重，反映在放射性肺炎、急性呼吸窘迫綜合徵、入院後24h內轉入ICU和有創通氣支持的頻率較高，以及LDH和CRP水平升高的頻率較高。研究人群的病例死亡率為21.8%（1761例死亡/8075例患者），但HCQ組（804/4542，17.7%）低於無HCQ組（957/3533，27.1%，P&lt;0.001）。兩組中類固醇的偶然使用率都很低，儘管HCQ組略高（分別為8.1% vs 5.9%）。另外，接受HCQ和AZM的761名參與者的死亡率為18.9%。

Table 2. COVID-19 Patients (n=8075) characteristics by treatment group.

表2. COVID-19患者(n=8075) 按治療組別特點分列


| <br> | *No./*總數*No. (%)* |
| --- | --- |
| <br> | HCQ n=4542 | 非HCQ n=3533 | *p* 值 |
| 人口特徵 |
| 年齡, 歲 | <br> | <br> | <br> |
|  16-30 | 62/4541 (1.4) | 72/3530 (2.0) | <br> |
|  31-44 | 372/4541 (8.2) | 175/3530 (5.0) | &lt;0.0001[\*](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb2fn3) |
|  45-64 | 1656/4541 (36.5) | 695/3530 (19.7) | <br> |
|  65-79 | 1395/4541 (30.7) | 1015/3530 (28.8) | <br> |
|  &gt;80 | 1056/4541 (23.3) | 1573/3530 (44.6) | <br> |
| 中位數 (IQR) | 66 (54-78) | 77 (63-85) | <br> |
| 男性 | 2646/4494 (58.9) | 1671/3492 (47.8) | &lt;0.0001[±](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb2fn4) |
| 既有病史 |
| 心血管疾病 | 1392/4542 (30.7) | 1444/3533 (40.9) | &lt;0.0001[±](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb2fn4) |
| 動脈高血壓 | 1757/4542 (38.7) | 1513/3533 (42.8) | 0.0002[±](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb2fn4) |
| 糖尿病 | 998/4542 (22.0) | 796/3533 (22.5) | 0.5498[±](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb2fn4) |
| 慢性腎病 | 508/4542 (11.2) | 585/3533 (16.6) | &lt;0.0001[±](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb2fn4) |
| 慢性肝病 | 122/4542 (2.7) | 99/3533 (2.8) | 0.7511[±](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb2fn4) |
| 慢性肺病 | 698/4542 (15.4) | 517/3533 (14.6) | 0.3599[±](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb2fn4) |
| 神經系統疾病 | 330/4542 (7.3) | 450/3533 (12.7) | &lt;0.0001[±](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb2fn4) |
| 認知障礙[1](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb2fn1) | 331/4260 (7.8) | 582/3266 (17.8) | &lt;0.0001[±](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb2fn4) |
| 免疫抑制性疾病 | 159/4542 (3.5) | 78/3533 (2.2) | 0.0006[±](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb2fn4) |
| 惡性腫瘤 | <br> | <br> | <br> |
|  實體瘤 | 314/4542 (6.9) | 345/3533 (9.8) | &lt;0.0001[±](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb2fn4) |
| 血液腫瘤 | 90/4542 (2.0) | 70/3533 (2.0) | 0.9995[±](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb2fn4) |
| 肥胖症[1](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb2fn1) | 297/2643 (11.2) | 186/2284 (8.1) | 0.0003[±](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb2fn4) |
| 目前吸煙者 | 183/2390 (7.7) | 196/1916 (10.2) | 0.0031[±](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb2fn4) |
| 藥物 |
| 血管緊張素轉化酶抑制劑 | 669/4541 (14.7) | 569/3531 (16.1) | 0.0874[±](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb2fn4) |
| 血管緊張素受體阻斷劑 | 388/4541 (8.5) | 318/3531 (9.0) | 0.4665[±](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb2fn4) |
| 入院時的實驗室參數 |
| 乳酸脫氫酶(U/L) | <br> | <br> | <br> |
| 中位數 (IQR) [No.] &gt;350 | 359 (270-497) [3890] | 314 (239-442) [2764] | &lt;0.0001[\*](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb2fn3) |
| <br> | 2036/3890 (52.3) | 1146/2764 (41.5) | &lt;0.0001[±](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb2fn4) |
| C反應蛋白(mg/L) | <br> | <br> | <br> |
| <br> | 68.9 (32.1-125.0) [4461] | 50.6 (16.0-105.2)[3340] | &lt;0.0001[\*](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb2fn3) |
| 中位數(IQR) [No.] &gt;150 | 835/4461 (18.7) | 471/3340 (14.1) | &lt;0.0001[±](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb2fn4) |
| paO2 (mmHg)中位數(IQR) [No.]&lt;60 | 66 (57-75) [3442] | 68 (58-80) [1967] | 0.0033[\*](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb2fn3) |
| <br> | 1046/3442 (30.4) | 557/1967 (28.3) | 0.1084[±](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb2fn4) |
| 臨床特徵 |
| 肺炎[2](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb2fn2) | 4055/4423 (91.7) | 2329/3313 (70.3) | &lt;0.0001[±](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb2fn4) |
| 急性呼吸窘迫綜合症 | 720/4306 (16.7) | 299/3320 (9.0) | &lt;0.0001[±](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb2fn4) |
| 有創通氣支持 | 503/4407 (11.4) | 114/3457 (3.3) | &lt;0.0001[±](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb2fn4) |
| 入院後24小時內進入重症監護室的情況 | 313/4539 (6.9) | 96/3529 (2.7) | &lt;0.0001[±](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb2fn4) |
| 從症狀發生到診斷的時間（天），中位數（IQR）[編號] | 6 (3-9) [4542] | 4 (1-8) [3049] | &lt;0.0001[\*](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb2fn3) |
| 住院時間（天數），中位數（IQR）[編號] | 9 (6-15) [3324] | 9 (4-17) [3526] | 0.2061[\*](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb2fn3) |
| 結果 |
| 從診斷到死亡的時間（天），中位數(IQR) [No.] | 8 (5-13) [4542] | 6 (4-12) [3533] | &lt;0.0001[\*](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb2fn3) |
| 死亡 | 804/4542 (17.7) | 957/3533 (27.1) | &lt;0.0001[±](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#tb2fn4) |


All the pre-existing conditions and COVID-19 features were reported as assessed by the clinician.

經臨床醫生評估，報告了所有已存在的疾病和COVID-19特徵

IQR：四分位數範圍；paO2：氧氣分壓

1 缺失的原因是數據收集開始的時間較晚

2 影像學診斷(胸部X光和/或CT掃描)

⁎ Wilcoxon檢驗

±秩方檢驗

Independent predictors of in-hospital mortality are shown in [Figure 2](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#fig0002). Age, male sex, cardiovascular disease, diabetes, chronic renal, liver and lung diseases, neurological disorders, immunosuppressive conditions, smoking status, as well as radiological pneumonia, acute respiratory distress syndrome, invasive ventilation support and immediate admission to ICU were all associated with a higher risk of in-hospital death. It was also the case for the measured laboratory parameters of severity at baseline. Treatment with HCQ alone was in contrast independently associated with decreased risk of in-hospital mortality (Adjusted hazard ratio [HR] 0.684, 95% confidence interval [CI] 0.617–0.758) compared to the no-HCQ group. [Figure 3](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#fig0003) shows the inverse propensity weighted standardized cumulative incidence of in-hospital death for each treatment with multiple imputations. From this model, estimated direct-adjusted mortality at 40 days was 19.1% with HCQ alone, and 26.5% with supportive care only.

院內死亡的獨立預測因素如圖2所示。年齡、性別男性、心血管疾病、糖尿病、慢性腎臟、肝臟和肺部疾病、神經系統疾病、免疫抑制性疾病、吸煙狀態以及放射性肺炎、急性呼吸窘迫綜合徵、有創通氣支持和立即進入ICU等均與院內死亡風險較高相關。基線時測量的實驗室嚴重程度參數也是如此。與不使用HCQ組相比，單獨使用HCQ治療與院內死亡風險降低獨立相關（調整後的危險比[HR]0.684，95%置信區間[CI]0.617-0.758）。圖3顯示了每種治療的反傾向加權標準化累積住院死亡發生率，並進行了多次推算。從該模型中，估計40天時的直接調整死亡率，單用HCQ為19.1%，僅用支持性護理為26.5%。

Figure 2. Independent predictors of in-hospital mortality among 8075 patients with COVID-19. Competing risks proportional hazards regression with robust standard errors analysing in-hospital death competing with alive discharge from hospital. HCQ: hydroxychloroquine, LDH: lactate deshydrogenase, CRP: C-reactive protein.

圖2. COVID-19患者住院死亡率的獨立預測因素。8075名COVID-19患者院內死亡率的獨立預測因素。競爭風險比例危險回歸與穩健標準誤差分析院內死亡與活著出院競爭。HCQ：羥氯喹，LDH：乳酸脫氫酶，CRP：C反應蛋白
![](https://s3.amazonaws.com/gnews-media-offload/wp-content/uploads/2020/09/01175822/fig.2_Traditional.jpg)
Figure 3. Cumulative incidence of in-hospital mortality. Inverse propensity weighted standardized cumulative incidence of in-hospital death according to treatment received. Hydroxychloroquine (HCQ) (blue line) vs no-HCQ (red line).

圖3. 住院死亡率累計發生率 院內死亡累計發生率。根據接受的治療，反傾向加權標準化的院內死亡累積發生率。羥氯喹（HCQ）（藍線）與無HCQ（紅線）
![](https://s3.amazonaws.com/gnews-media-offload/wp-content/uploads/2020/09/01175833/fig.3_Traditional.jpg)
Next, we compared the association between HCQ treatment and in-hospital mortality in patients diagnosed and treated within five days after onset of symptoms (early diagnosis, n= 3975) to those diagnosed more than 5 days later (late diagnosis, n=3487). Compared to the no-HCQ group, administration of HCQ appears to be associated to a lower risk of death in both the early diagnosis group (Adjusted HR 0.701, 95% CI 0.617–0.796) and the late diagnosis group (Adjusted HR 0.647, 95% CI 0.525–0.797).

接下來，我們比較了症狀出現後5天內診斷和治療的患者（早期診斷，n=3975）與5天後診斷的患者（晚期診斷，n=3487）的HCQ治療與住院死亡率之間的關係。與無HCQ組相比，在早期診斷組（調整後HR為0.701，95%CI為0.617-0.796）和晚期診斷組（調整後HR為0.647，95%CI為0.525-0.797）中，服用HCQ似乎與較低的死亡風險有關。

**4. Discussion 讨论**

In this large analysis of patients admitted for COVID-19 in Belgium, HCQ monotherapy administered at a dosage of 2400 mg over five days was independently associated with a lower in-hospital mortality rate compared to patients treated with supportive care only, even after adjustment for age, major comorbidities and disease severity at admission. Importantly, mortality was reduced regardless of the timing from symptom onset to diagnosis and HCQ treatment initiation.

在對比利時因COVID-19入院的患者進行的這項大型分析中，與僅接受支持性護理的患者相比，5天內以2400mg的劑量進行HCQ單藥治療與較低的住院死亡率獨立相關，即使在調整了年齡、主要合併症和入院時的疾病嚴重程度後也是如此。重要的是，無論從症狀發生到診斷和HCQ治療開始的時間如何，死亡率都會降低。

Our study has several limitations and strengths. It is an observational study of data collected using standardized report forms during the most critical phase of the epidemic in Belgium. The cohort was established within an ongoing surveillance that aims at monitoring the epidemic and identifying risk factors for severe COVID-19 and unfavourable outcome. The evaluation of HCQ efficacy in this population was therefore not the primary objective of the data collection itself. Also, the actual HCQ dosage was not systematically checked, but qualitative surveys pointed out that the “low-dose” recommendation was very well adhered to, since the risk of dose-dependent cardiotoxicity and the necessary precautions of use in patients at risk were particularly stressed in the treatment guidance [\[8\]](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#bib0008). Not surprisingly, HCQ has been less administered in several groups of patients with pre-existing conditions or co-medications which corresponded to contra-indications of its use (cardiac and renal diseases). The implementation of this surveillance during the initial phase of the epidemic when hospitals were under pressure and its non-mandatory nature resulted in missing admission or discharge report forms for a sizeable proportion of patients. The absence of difference in the baseline characteristics and in outcome for subgroups with missing data and the study population is somehow reassuring, although some hidden sources of bias cannot be fully excluded. Strengths of this study include the very large sample size obtained in a timely manner, the strict comparison between groups exposed to HCQ in monotherapy and to supportive care only (with no other COVID-19 treatments as confounders), the multi-centric design covering the vast majority of Belgian hospitals and the real-life representativeness of the data. Indeed, this hospital-based surveillance captured complete admission and discharge information for 64% (10920/17052) of all aggregated COVID-19 patients admitted across the country until the 24th of May [\[25\]](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#bib0025). Finally, rigorous sensitivity analysis taking into account censored data and immortal bias all confirmed the positive impact of HCQ on in-hospital mortality.

我們的研究有幾個局限性和優勢。這是一項觀察性研究，是在比利時流行病最關鍵階段使用標準化報告表收集的數據。該隊列是在一個正在進行的監測中建立的，該監測的目的是監測流行病並確定嚴重COVID-19和不利結果的風險因素。因此，評估HCQ在該人群中的療效並不是數據收集本身的主要目的。另外，HCQ的實際用量也沒有進行系統的檢查，但定性調查指出，”低劑量 “的建議得到了很好的遵守，因為在治療指南中特別強調了劑量依賴性心臟毒性的風險和高危患者使用的必要注意事項[8]。不足為奇的是，在幾組已有疾病或聯合用藥的患者中，HCQ的使用量較少，而這些疾病或聯合用藥符合其使用禁忌症（心臟和腎臟疾病）。在疫情初期實施該監測時，醫院壓力較大，且該監測為非強制性的，導致相當一部分患者的入院或出院報告單缺失。雖然不能完全排除一些隱藏的偏倚來源，但缺失數據的亞組和研究人群的基線特徵和結果沒有差異，這在某種程度上令人欣慰。這項研究的優勢包括：及時獲得了非常大的樣本量，嚴格比較了單次治療中暴露於HCQ的組別和只暴露於支持性護理的組別（沒有其他COVID-19治療作為混雜因素），覆蓋比利時絕大多數醫院的多中心設計，以及數據的現實生活代表性。事實上，此次基於醫院的監測捕捉到了截至5月24日全國所有匯總的COVID-19住院患者中64%（10920/17052）的完整入院和出院信息[25]。最後，考慮到刪減數據和不死偏向的嚴格敏感性分析都證實了HCQ對院內死亡率的積極影響。

This nationwide observational study provides a robust description of the COVID-19 patients admitted in Belgian hospitals. The demographic and clinical characteristics were similar to hospital cohorts reported in other countries, with a large proportion of patients with well-established risk factors for COVID-19 complications. The observed in-hospital mortality rate (about 21.8%) was in line with that of previous observational studies and ongoing trials [\[26\]](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#bib0026), [\[27\]](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#bib0027), [\[28\]](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#bib0028). Risk factors of death were comparable to previous clinical experience. Notably, we found that biological markers previously related to disease severity and mortality in univariate analysis (increased CRP and LDH) [\[29\]](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#bib0029) were independently associated with mortality in our study. Other well-established predictors of mortality such as lymphopenia and increased levels of D-dimer were not recorded in our dataset. High D-dimer levels have been meanwhile associated with increased risk of thrombotic events, a major cause of death in hospitalized COVID-19 patients [[30](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#bib0030),[31](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#bib0031)].

這項全國性的觀察研究對比利時醫院收治的COVID-19患者進行了有力的描述。人口學和臨床特徵與其他國家報道的醫院隊列相似，大部分患者具有COVID-19併發症的既定風險因素。觀察到的院內死亡率（約21.8%）與以往觀察性研究和正在進行的試驗[26], [27], [28]一致。死亡的危險因素與以往的臨床經驗相當。值得注意的是，我們發現之前在單變量分析中與疾病嚴重性和死亡率相關的生物標誌物（CRP和LDH增加） [29]在我們的研究中與死亡率獨立相關。我們的數據集中沒有記錄其他成熟的死亡率預測因子，如淋巴細胞減少症和D-二聚體水平增加。同時，高D-二聚體水平與血栓事件風險增加有關，而血栓事件是住院COVID-19患者死亡的主要原因[30,31]。

Interestingly, we observed that patients who died in the hospital, had on average a shorter duration of symptoms before admission, suggesting that abrupt clinical deterioration is associated with worst prognosis. More research is required to clarify the phenotype of this subgroup of patients, to assess whether patients who develop signs of severity very soon after the onset of symptoms require more intensive care earlier, and to investigate whether very early predictors of subsequent severity and targeted (pre-hospital) interventions could prevent admission due to acute complications.

有趣的是，我們觀察到，在醫院死亡的患者，入院前的症狀平均持續時間較短，這表明臨床突然惡化與最差的預後有關。需要進行更多的研究，以明確這類患者亞群的表型，評估在症狀發生後很快就出現嚴重症狀的患者是否需要更早的重症監護，並研究非常早期的後續嚴重性預測因素和有針對性的（院前）干預措施是否可以防止因急性併發症而入院。

In the context of the COVID-19 pandemic, HCQ therapy has been in the centre of debates, between hype and bashing, within and beyond the scientific community. Uncertainty about treatment efficacy relies mainly on the observational nature of the published studies so far and the major risks of bias and confounders. Many small single-centre retrospective studies did not find any impact of HCQ treatment on outcome in hospitalized COVID-19 patients [[11](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#bib0011),[\[13\]](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#bib0013), [\[14\]](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#bib0014), [\[15\]](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#bib0015), [\[16\]](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#bib0016)], but were not powered to explore associations with mortality endpoint through robust multivariate analysis. Recently, larger observational studies found that the use of HCQ alone or in combination with AZM was independently associated with lower in-hospital mortality [\[17\]](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#bib0017), [\[18\]](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#bib0018), [\[19\]](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#bib0019), in line with our results. Some therapeutic differences have however to be highlighted, that impede full comparison of these studies with our data. In Lagier’s study [\[17\]](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#bib0017), HCQ dosage was 6000 mg in total over 10 days, and the vast majority of participants were given AZM concomitantly. In Mikami’s study [\[18\]](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#bib0018), the HCQ dosage was not reported, but most hospitalized patients were also exposed to a combination of HCQ and AZM. Finally, Arshad et al. used the same HCQ dosage as in our study, and reported specifically on the subgroup treated with HCQ, but a large proportion of participants were also given steroids, which might have been beneficial in severe COVID-19 cases [[19](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#bib0019),[32](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#bib0032)]. Of note, in our dataset, corticosteroids uptake was low in both groups. In Belgium, AZM was not recommended due to the lack of robust information on viral efficacy at the time of writing the guidance. It has however been administered in combination with HCQ in 761 patients in our real-life database (but excluded from this analysis). The combination AZM-HCQ treatment was associated to a decrease in mortality similar to that of HCQ alone (data not shown).

在COVID-19大流行的背景下，HCQ療法一直是科學界內外爭論的焦點，是炒作還是抨擊。療效的不確定性主要依賴於迄今為止已發表的研究的觀察性，以及偏見和混雜因素的主要風險。許多小型單中心回顧性研究沒有發現HCQ治療對住院COVID-19患者的結局有任何影響[11，[13]，[14]，[15]，[16]]，但沒有通過穩健的多變量分析來探索與死亡率終點的關聯。最近，較大的觀察性研究發現，單獨使用HCQ或與AZM聯合使用與較低的院內死亡率獨立相關[17]，[18]，[19]，與我們的結果一致。然而，需要強調的是，一些治療上的差異阻礙了這些研究與我們數據的全面比較。在Lagier的研究[17]中，HCQ劑量為10天共6000mg，絕大多數參與者同時服用AZM。在Mikami的研究中[18]，HCQ劑量未見報道，但大多數住院患者也是同時接觸HCQ和AZM。最後，Arshad等人使用了與我們研究中相同的HCQ劑量，並具體報道了接受HCQ治療的亞組，但很大一部分參與者也被給予類固醇，這可能對嚴重的COVID-19病例有益[19,32]。值得注意的是，在我們的數據集中，兩組中皮質類固醇的吸收率都很低。在比利時，由於撰寫指南時缺乏病毒療效的有力信息，因此不推薦使用AZM。然而，在我們的真實數據庫中，已經有761例患者聯合使用了該藥（但不包括在本次分析中）。AZM-HCQ聯合治療與單用HCQ的死亡率下降相似（數據未顯示）。

Although observational studies, even of large scale, do not provide final conclusions on treatment efficacy, their results are important to consider to guide clinical trials. Well-designed prospective studies combined with large randomized control trials should provide definitive evidence about the clinical impact of HCQ in severe hospitalized and in mild ambulatory COVID-19 patients. Meanwhile, in a preprint publication at the time of writing, the results of the RECOVERY trial did not show any clinical benefit (death or discharge) in the high dose HCQ arm (9200 mg in total over 10 days) compared to usual care in hospitalized COVID-19 patients (median number of days from symptom onset to randomization: 9 days) [\[20\]](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#bib0020). Of note, the dose administered during the first 24h (2400 mg) is equivalent to the dose administered during 5 days in Belgium. The pharmacokinetic rationale for the high dosage remains poorly described. Moreover, 10% of the patients included in the HCQ arm had negative SARS-CoV-2 test and mortality was high in both groups (25%), indicating advanced disease.

雖然觀察性研究，即使是大規模的研究，也不能提供治療效果的最終結論，但其結果對於指導臨床試驗具有重要意義。設計良好的前瞻性研究與大型隨機對照試驗相結合，應能提供關於HCQ對重度住院患者和輕度非臥床COVID-19患者的臨床影響的確切證據。同時，在撰寫本文時發表的一份預印本中，RECOVERY試驗結果顯示，與住院COVID-19患者的常規護理相比，高劑量HCQ組（10天共9200mg）沒有任何臨床獲益（死亡或出院）（從症狀發生到隨機化的中位天數：9天）[20]。值得注意的是，前24h內的給藥劑量（2400mg）相當於比利時5天內的給藥劑量。高劑量的藥代動力學原理仍描述不清。此外，納入HCQ組的患者中，10%的患者SARS-CoV-2檢測陰性，兩組的死亡率都很高（25%），表明疾病已到晚期。

While both CQ and HCQ have *in vitro* antiviral activity against SARS-CoV-2 [[3](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#bib0003),[4](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#bib0004),[9](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#bib0009)], concerns about a real antiviral activity *in vivo* have emerged early in the pandemic based on previous experience in other viral infections [\[33\]](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#bib0033). Antiviral efficacy of HCQ in humans has been poorly studied so far with adequate methods. Questions have also been raised whether safe HCQ dosages are sufficient to reach antiviral activity in target pulmonary cells [\[34\]](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#bib0034). Translating *in vitro* data into *in vivo* drug concentration in tissue appears particularly challenging for HCQ, as plasma concentrations do not appear to be a reliable surrogate [\[35\]](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#bib0035). Preprint studies in animal models (non-humans primates and Syrian hamsters) also suggest that HCQ has no antiviral efficacy [[36](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#bib0036),[37](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#bib0037)]. Clinical efficacy might however be mediated through immunomodulatory mechanisms [\[7\]](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#bib0007), preventing the progression toward severe disease with over-inflammatory responses by dampening the cytokine storm [\[38\]](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#bib0038). HCQ has indeed been shown to decrease the production of pro-inflammatory cytokines, both *ex vivo* and in lung explant model [[5](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#bib0005),[39](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#bib0039),[40](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#bib0040)]. In the same line, use of low-dose dexamethasone (one of the RECOVERY arm) was recently reported to significantly decrease mortality in COVID-19 patients requiring oxygen [\[28\]](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#bib0028). Also, HCQ has been suggested to have some anticoagulant properties that may be beneficial in preventing thrombotic events in complement to low-molecular weight heparin [\[41\]](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#bib0041).

雖然CQ和HCQ都對SARS-CoV-2具有體外抗病毒活性[3,4,9]，但根據以往在其他病毒感染中的經驗，在流行病早期就出現了對體內真正抗病毒活性的擔憂 [33]。到目前為止，HCQ在人體中的抗病毒療效研究還沒有足夠的方法。也有人提出了安全的HCQ劑量是否足以在靶肺細胞中達到抗病毒活性的問題 [34]。對於HCQ來說，將體外數據轉化為組織中的體內藥物濃度似乎特別具有挑戰性，因為血漿濃度似乎不是一個可靠的代用物 [35]。在動物模型（非人類靈長類動物和敘利亞倉鼠）中的印前研究也表明，HCQ沒有抗病毒功效[36,37]。但臨床療效可能是通過免疫調節機制[7]，通過抑制細胞因子風暴 [38]，防止過度炎症反應向嚴重疾病發展。HCQ確實已經被證明可以減少促炎細胞因子的產生，無論是在體內還是在肺移植模型中[5,39,40]。同樣，最近有報道稱，使用低劑量地塞米松（RECOVERY臂之一）可以顯著降低需要吸氧的COVID-19患者的死亡率[28]。另外，有人認為HCQ具有一定的抗凝血特性，可能有利於預防血栓事件，與低分子量肝素互補[41]。

The potential detrimental effect of HCQ, mainly due to dose-dependent cardiotoxicity, has become a major clinical concern, especially following the publication of an article that reported an association between HCQ therapy and increased in-hospital mortality, but that was retracted shortly after [\[42\]](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#bib0042). A randomized controlled trial evaluating high (12000 mg over 10 days) and low CQ dosage was halted prematurely due to serious toxicity in the high dose group [\[43\]](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#bib0043). However, many studies have meanwhile reported on the safety of a short-term/low dosage course of HCQ monotherapy [[16](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#bib0016),[44](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#bib0044)]. Our study provides further support to the claim that this regimen is not associated with increased short term risk of cardiotoxicity and mortality in the hospital setting and in well-selected COVID-19 patients. Accordingly, as of 17 June 2020, the Federal Agency for Medicines and Health Products had registered in total 8 reports of adverse reactions suspected to be associated with HCQ use for the treatment of COVID-19 in Belgium, among which 3 cases of cardiac toxicity (all having received concomitant medication) and no reported deaths [\[45\]](https://www.sciencedirect.com/science/article/pii/S0924857920303423?via%253Dihub#bib0045).

HCQ的潛在不利影響，主要是由於劑量依賴性的心臟毒性，已成為臨床上的主要關注點，特別是在一篇文章發表後，該文章報道了HCQ治療與院內死亡率增加之間的關係，但不久後又被收回[42]。一項評估高劑量（10天12000mg）和低劑量CQ的隨機對照試驗由於高劑量組的嚴重毒性而提前停止[43]。然而，許多研究同時報道了HCQ單藥治療的短期/低劑量療程的安全性[16,44]。我們的研究進一步支持了這樣的說法，即在醫院環境下和精心選擇的COVID-19患者中，該方案與心臟毒性和死亡率的短期風險增加無關。因此，截至2020年6月17日，比利時聯邦藥品和健康產品管理局共登記了8例疑似與HCQ用於治療COVID-19相關的不良反應報告，其中3例心臟毒性（均接受過伴隨藥物治療），無死亡報告 [45]。

In conclusion, in this large nationwide observational study of patients hospitalized with COVID-19, HCQ monotherapy administered at a dosage of 2400 mg over five days was independently associated with significant decrease in mortality compared to patients not treated with HCQ. This impact was observed in both early and late treatment group, suggesting that this benefit might be mediated by immunomodulatory properties, a hypothesis worth addressing as evidence of an antiviral activity of HCQ on SARS-CoV-2 appears increasingly inconsistent. Considering the availability and cheapness of HCQ, it seems worth further investigating the clinical effect of optimized dosage of HCQ and designing add-on studies in ongoing trials to monitor, beyond the viral shedding and infectiousness, a relevant set of inflammatory markers during the course of SARS-CoV-2 infection.

總之，在這項針對COVID-19住院患者的全國性大型觀察研究中，與未接受HCQ治療的患者相比，5天內以2400mg的劑量進行HCQ單藥治療與死亡率的顯著下降獨立相關。這種影響在早期和晚期治療組中都能觀察到，表明這種益處可能是由免疫調節特性所介導的，這是一個值得探討的假說，因為HCQ對SARS-CoV-2的抗病毒活性的證據似乎越來越不一致。考慮到HCQ的可獲得性和廉價性，似乎值得進一步研究優化劑量的HCQ的臨床效果，並在正在進行的試驗中設計附加研究，以監測SARS-CoV-2感染過程中除了病毒脫落和傳染性之外的一組相關炎症標誌物。

翻譯：【Naomi (文花開)】編輯：【Michelle】

戰友之家玫瑰園小隊出品

相關新聞：

[意大利最新研究表明羥氯喹加阿奇霉素降低60%以上死亡率](https://gnews.org/zh-hant/282190/)

[國際傳染病學雜誌發表《羥氯喹、阿奇霉素和聯合用藥治療新型冠狀病毒肺炎住院患者》](https://gnews.org/zh-hant/259104/)

[亨利福特衛生系統研究顯示：使用羥氯喹治療CCP病毒患者可顯著降低死亡率](https://gnews.org/zh-hant/258573/)

1
